By the Top Tier Newswire AI Desk · August 26, 2026 at 3:24 PM ET · reviewed against 1 wire stories
NANOBIOTIX S A ADR (NBTX) is up +5.97% in the latest session. Our newswire has captured 1 story on NBTX across 1 source in the last 36 hours, with AI sentiment reading mixed (avg 50/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
NBTX stock rose 5.97% to $43.99 on Monday as the biotech firm continued to draw attention from analysts and investors. The move came amid recent developments including a raised price target from Leerink Partners and progress in clinical trials. The stock's intraday performance showed a volatile session with a high of $43.99 and a low of $39.89 before closing near the session high.
What Happened
Nanobiotix announced an update to its share capital and voting rights as of July 31, 2026, disclosing 50,833,462 shares outstanding. This update was reported by TipRanks. Separately, Leerink Partners maintained its Outperform rating on Nanobiotix and raised its price target to $46. The firm also highlighted an 85.7% response rate in the Phase 2 JNJ-1900 NSCLC study during Q1 2026. The company also received FDA acceptance of the NANORAY-312 protocol amendment. In addition, Nanobiotix was added to the Euronext Tech Leaders Program and Index and launched a global follow-on offering of approximately €75 million to advance its Nanoprimer platform.
What The Data Shows
The stock opened at $41.33 and traded with a high volatility profile, reaching a session high of $43.99 at 3:15 PM ET. Volume in the session was 0.1 million shares, which is 1.1 times the 3-month average. The 52-week tape showed 10 fresh 52-week highs and 10 fresh 52-week lows on August 26, 2026. The stock remains unprofitable with a trailing 12-month revenue decline of 553.2% and a net margin of -73.5%. Its market capitalization is $2.0 billion, and it has a beta of 0.57, indicating lower volatility than the market.
What To Watch
Nanobiotix has no upcoming earnings date. Investors should monitor the breadth of analyst coverage and any further developments from its clinical trials or capital-raising efforts.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
NBTX · Aug 26 session (5-min) · +7.20% vs prior close · updated 8:52 PM ETAI sentiment, last 36h · averaged over 1 story · 50/100 neutral
The headlines behind the move
Story flow · 1 story on the wire, last 36h · hover or tap a dot for the headline
18d agoTipRanksNEUTRAL 50General
Nanobiotix Updates Share Capital and Voting Rights as of July 31, 2026
Nanobiotix ( ($FR:NANO) ) just unveiled an announcement. Nanobiotix reported that as of July 31, 2026, it had 50,833,462 shares outstanding and 54,534,179 theoretic...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →